Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley T Crooke

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Health Security|March 28, 2015
Health security preparedness and industry trendsStanley T Crooke
Nucleic Acid Therapeutics|September 14, 2021
Addressing the Needs of Patients with Ultra-Rare Mutations One Patient at a Time: The n-Lorem ApproachStanley T Crooke
Journal of Clinical Pharmacology|September 19, 2017
RNA Therapeutics in Oncology: Advances, Challenges, and Future DirectionsA Robert MacLeod, Stanley T Crooke
Plos One|October 10, 2014
Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanismsTimothy A Vickers, Stanley T Crooke
Biochimica Et Biophysica Acta|July 31, 2013
RNA helicase A is not required for RISC activityXue-Hai Liang, Stanley T Crooke
Nucleic Acids Research|September 19, 2015
The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNATimothy A Vickers, Stanley T Crooke
Nature Biotechnology|March 2, 2026
Establishing a commercial solution for extremely rare genetic diseasesStanley T Crooke, Andrew W Lo
Nucleic Acids Research|March 17, 2012
siRNAs targeted to certain polyadenylation sites promote specific, RISC-independent degradation of messenger RNAsTimothy A Vickers, Stanley T Crooke
British Journal of Clinical Pharmacology|September 28, 2012
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein BStanley T Crooke, Richard S Geary
Nucleic Acids Research|February 16, 2011
Depletion of key protein components of the RISC pathway impairs pre-ribosomal RNA processingXue-Hai Liang, Stanley T Crooke
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Health Security|March 28, 2015
Health security preparedness and industry trendsStanley T Crooke
Nucleic Acid Therapeutics|September 14, 2021
Addressing the Needs of Patients with Ultra-Rare Mutations One Patient at a Time: The n-Lorem ApproachStanley T Crooke
Journal of Clinical Pharmacology|September 19, 2017
RNA Therapeutics in Oncology: Advances, Challenges, and Future DirectionsA Robert MacLeod, Stanley T Crooke
Plos One|October 10, 2014
Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanismsTimothy A Vickers, Stanley T Crooke
Biochimica Et Biophysica Acta|July 31, 2013
RNA helicase A is not required for RISC activityXue-Hai Liang, Stanley T Crooke
Nucleic Acids Research|September 19, 2015
The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNATimothy A Vickers, Stanley T Crooke
Nature Biotechnology|March 2, 2026
Establishing a commercial solution for extremely rare genetic diseasesStanley T Crooke, Andrew W Lo
Nucleic Acids Research|March 17, 2012
siRNAs targeted to certain polyadenylation sites promote specific, RISC-independent degradation of messenger RNAsTimothy A Vickers, Stanley T Crooke
British Journal of Clinical Pharmacology|September 28, 2012
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein BStanley T Crooke, Richard S Geary
Nucleic Acids Research|February 16, 2011
Depletion of key protein components of the RISC pathway impairs pre-ribosomal RNA processingXue-Hai Liang, Stanley T Crooke
Pageof 13